IMR Press / EJGO / Volume 36 / Issue 1 / DOI: 10.12892/ejgo2556.2015

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer
Show Less
1 Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou (People’s Republic of China)
Eur. J. Gynaecol. Oncol. 2015, 36(1), 54–58; https://doi.org/10.12892/ejgo2556.2015
Published: 10 February 2015
Abstract

Objectives: To investigate the efficacy and toxicities of combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy (NACT) in locally advanced cervical cancer. Materials and Methods: The authors retrospectively reviewed the clinical records of patients with cervical cancer who received NACT with liposomal paclitaxel and cisplatin at Sun Yat-sen University Cancer Center from April 1, 2008 to December 31, 2012. Liposomal paclitaxel and cisplatin was administrated intravenously at a dose of 175 mg/m2 and 75 mg/m2, respectively. Results: The total response rate was 86.1% (62/72) including a complete response and partial response rate of 27.8 % (20/72) and 58.3% (42/72), respectively. Stable disease was observed in 12.5 % (9/72) of patients and progressive disease in 1.4 % (1/72). Hematological toxicities were the major dose-limiting toxicities. Grade 3/4 neutropenia and anemia developed in 18.1% (13/72) and 6.9% (5/72) of patients, respectively. Peripheral neuropathy occurred in 6.9% (5/72) of patients (all grade 1). Conclusion: the study findings support further evaluation of liposomal paclitaxel with cisplatin as an additional chemotherapy regimen which may be efficacious and tolerable in the NACT of cervical cancer.
Keywords
Cervical cancer
Neoadjuvant chemotherapy
Liposomal paclitaxel
Locally advanced
Share
Back to top